Irvine, Calif.-based Edwards Lifesciences Corp. unveiled results from the COMMENCE clinical study, with data showing that the company's bioprosthetic surgical aortic valves featuring its Resilia tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up. Read More
